Abdul-Ghani Lab

Research focus

NIH R01 · 2024

Comparative Effectiveness of Two Initial Combination Therapies in Patients with New Onset Diabetes

Project Summary/Abstract The current ADA/EASD recommendation for glucose control in newly diagnosed T2DM patients who are free from CVD and renal disease is to start on metformin and sequentially add other glucose lowering agents upon metformin failure to maintain HbA1c <7.0%. The recently completed GRADE study, which had tested the efficacy of 4 glucose lowering agents (sitagliptin, glimepiride, liraglutide and glargine insulin) in maintaining the treatment goal in metformin failing T2DM patients, has demonstrated that the vast majority (67-75%) failed to maintain the treatment goal at 5 years, suggesting of inability of sequential add on approach on maintaining durable reduction in the…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.